David R. Epstein Sells 370 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 370 shares of Tempus AI stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $53.31, for a total transaction of $19,724.70. Following the completion of the sale, the director now owns 27,524 shares in the company, valued at approximately $1,467,304.44. This represents a 1.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Tempus AI Price Performance

Shares of TEM traded up $7.33 during trading hours on Wednesday, reaching $69.18. The stock had a trading volume of 22,552,156 shares, compared to its average volume of 11,320,281. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The firm has a 50-day simple moving average of $44.20 and a 200 day simple moving average of $48.58.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on TEM shares. TD Cowen reaffirmed a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday. Bank of America increased their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Guggenheim initiated coverage on Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $58.55.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEM. First Horizon Advisors Inc. purchased a new stake in shares of Tempus AI in the 3rd quarter valued at $30,000. FNY Investment Advisers LLC purchased a new stake in Tempus AI during the fourth quarter valued at about $67,000. IFP Advisors Inc bought a new position in shares of Tempus AI during the fourth quarter valued at about $76,000. US Bancorp DE purchased a new position in shares of Tempus AI in the fourth quarter worth about $80,000. Finally, Vestor Capital LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at about $153,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.